Menu

Plenty of growth lies ahead for these top healthcare companies.

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

January 14, 2026

On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari...

Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS

January 13, 2026

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment Candidate ↗

January 13, 2026

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Compelling Value Stock Candidate ↗

January 01, 2026

Via Chartmill

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 11, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

The Best Stocks to Invest $50,000 in Right Now ↗

January 11, 2026

These stocks should be good bets in the new year.

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

Topics Artificial Intelligence

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 ↗

January 09, 2026

It could be another tough year for the once-soaring drugmaker.

Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...

Topics Intellectual Property

Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge

January 07, 2026

Via PredictStreet

Topics Economy Initial Public Offering Intellectual Property

Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies

January 07, 2026

Check out the companies making headlines yesterday:

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 3.8% in the afternoon session after Wolfe Research upgraded the stock from "Peer Perform" to "Outperform" and issued a $548 price...

Topics Artificial Intelligence

Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why

January 06, 2026

Investing in a few of these players could increase the diversification of your portfolio.

My 10 Top Stocks to Buy to Start the New Year Off Right ↗

January 05, 2026

BofA Unveils Q1 2026 Top Stock Picks: High-Conviction Bets on AI Infrastructure and Health Care Valuations

Topics Artificial Intelligence

January 02, 2026

As the opening bells of 2026 ring across Wall Street, Bank of America Securities has released its highly anticipated "Top 10 U.S. Stock Ideas for Q1 2026." The report, a cornerstone for institutional...

These three stocks could make 2026 a happy new year for investors.

Topics Artificial Intelligence Economy

The Best Stocks to Invest $1,000 in to Start the New Year Off Right ↗

January 01, 2026

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Topics Artificial Intelligence

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Topics Artificial Intelligence ETFs Economy

Stay informed with the top movers within the S&P500 index on Tuesday. ↗

December 30, 2025

Via Chartmill

Discover which S&P500 stocks are making waves on Tuesday. ↗

December 30, 2025

Via Chartmill

2 Growth Stocks to Buy For 2026 and Beyond ↗

December 30, 2025

Neither had a great year in 2025, but the future is looking bright.

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or...

Topics Economy

2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down

December 28, 2025

Growth stocks fall in and out of favor with investors, but quality businesses are always worth buying.

Topics Electric Vehicles World Trade

3 Supercharged Growth Stocks to Buy and Hold Into the 2030s ↗

December 28, 2025

This stock is a great choice for cautious and aggressive investors.

Topics Artificial Intelligence

Forget Moderna Stock, This is a Much Better Buy ↗

December 27, 2025

The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy

Topics Intellectual Property

December 24, 2025

On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),...

Via PredictStreet

Topics Economy

Is CRISPR Therapeutics Stock Yesterday's News? ↗

December 24, 2025

The biotech sells blood disorders treatment, Casgevy.

As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global...

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

December 22, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive

December 22, 2025

Via PredictStreet

Topics Earnings Initial Public Offering Intellectual Property

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A GARP Case Study in Affordable Growth ↗

December 22, 2025

Vertex Pharmaceuticals (VRTX) exemplifies GARP investing, offering strong earnings growth, top profitability, and a debt-free balance sheet at a reasonable market valuation.

Via Chartmill

2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky

December 21, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Next year could be crucial for the company as sales for its only approved treatment could take off.

Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗

December 19, 2025

Since June 2025, Vertex Pharmaceuticals has been in a holding pattern, posting a small return of 0.5% while floating around $450.68. The stock also fell short of the S&P 500’s 13.6% gain during that...

2 Reasons to Watch VRTX and 1 to Stay Cautious

December 17, 2025